Tag Archives: Cell

Cutaneous HPV linked to squamous cell carcinoma

Cutaneous HPV linked to squamous cell carcinoma
Squamous cell carcinoma (SCC) was positively associated with antibodies to several types of cutaneous human papillomavirus (HPV) in a case control study. Cutaneous HPV infection, which differs from the mucosal HPV infection associated with cervical
Read more on Oncology Nurse Advisor

Paper highlights clinical and immunological activity of immatics' IMA901 in
immatics biotechnologies GmbH, a clinical-stage biopharmaceutical company developing advanced therapeutic vaccines that are active against cancer, today announced that key data covering the scientific and clinical development of its lead cancer vaccine
Read more on News-Medical.net

Pfizer Reports Results From Phase 3 Study Of Torisel (temsirolimus) In
Pfizer Inc. announced today that the Phase 3 INTORACT trial (B1771006), evaluating the combination of bevacizumab plus TORISEL® (temsirolimus) compared with bevacizumab plus interferon-alfa-2a (IFN-a-2a) in the first-line treatment of patients with
Read more on eYugoslavia.com

MultiCell announces new cancer therapeutics preclinical results
The results will further aid mechanistic and in vivo studies exploring the safety, effectiveness and utility of MCT-465 and MCT-485 as therapeutic agents to treat hepatocellular carcinoma and other cancers. Primary liver cancer results from Hepatitis B
Read more on Pharmaceutical Business Review

Prior Basal Cell Carcinoma Is Main Predictor of Future BCC

Prior Basal Cell Carcinoma Is Main Predictor of Future BCC
MONDAY, July 30 (HealthDay News) — Prior basal cell carcinoma (BCC) is the greatest predictor of future incidence of BCC, according to a study published online July 19 in the Journal of Investigative Dermatology. In a prospective six-year trial, Robert K.
Read more on Doctors Lounge

Skin cancer treatments without surgery
There are many types of skin cancer, the most common being basal cell carcinoma (80 percent), squamous cell carcinoma (16 percent) and malignant melanoma (4 percent). This is not a complete least as there are a number of other unusual types we see.
Read more on Tampa Bay Newspapers

Cell Tower Lease Advisor-Vertical Consultants Adds AK Self-Storage Co as Client


Nashville, TN (PRWEB) August 08, 2012

Vertical Consultants welcomes A&E Self-Storage, Inc., an Alaska based real estate developer, as its newest client. Vertical Consultants was engaged by A&E Self-Storage to provide counsel and optimize opportunities regarding its telecom assets associated with its properties located in Alaska.

Hugh Odom, the President of Vertical Consultants, states ?We welcome A&E Self-Storage to our expanding nationwide list of self-storage owner clients. An increasing number of self-storage owners/operators are realizing the immediate and long-term significant value Vertical Consultants can bring by delivering additional revenue sources and optimizing their current cell tower leases that until now has been overlooked and underutilized.?

Vertical Consultants, since inception, has solidified its position the only true land owner advocate and resource for property owners seeking to fully benefit in their transactions with the largest global telecom companies in the world. Vertical Consultants has established itself as a source of data for property owners and a medium for these same property owners to obtain true value for the use and occupancy of their property.

Vertical Consultants was founded in 2010 by Hugh Odom and is comprised of a group of wireless industry veterans with decades of combined experience. Vertical Consultants specializes in issues surrounding the wireless telecom industry and prides itself as a source of information for property owners. Vertical Consultants experience in the industry allows it to offer its clients unmatched expertise, services and results. Unlike others in their field, Vertical Consultants is able to handle every aspect of the issues surrounding a cell tower, rooftop or any other type of telecom lease, from start to finish. To learn more visit http://www.vertical-consultants.com or contact Vertical Consultants at info(at)vertical-consultants(dot)com or 877.456.7552.

###







Dr. Uffe Ravnskov Announced Today His Review of “How Statin Drugs Really Lower Cholesterol And Kill You One Cell At A Time” from His Headquarters in Stockholm, Sweden


Stockholm, Sweden (PRWEB) July 16, 2012

“How Statin Drugs Really Lower Cholesterol and Kill You One Cell At A Time” was reviewed by Dr. Uffe Ravnskov from his headquarters in Stockholm, Sweden. Dr. Ravnskov made the following observations:

Ravnskov said he learned more about the background of the creation Statin Drugs than he knew before. “Scary reading indeed.” Dr. Ravnskov said he didn’t know about Marvin Siperstein and he will start reading Dr. Siperstein’s papers.

Ravnskov said he was depressed when he learned about Brown and Goldstein?s fraudulent behavior and suggested the Yosephs send a copy of their book to Peter Englund, the secretary of the Nobel Prize committee. “Now I understand why I never got an answer from these guys ? I sent them a long kind, letter some years ago to tell them about the many clinical and epidemiological observations that contradicted their hypothesis. Naively I thought that they, being biochemists, didn?t know about them.”

Dr. Ravnskov noted that there are many interesting quotations without references and requested references to the following:

Page 32. Endo?s paper about dogs and cancer

Page 33. Sankyo?s paper about dogs and lymphoma

Page 143. The paper that reported no effects of statin treatment in homozygous FH patients

Page 197 Toberts cholestyramin trial

Page 211 Toberts paper about cataract in lovastatin consumers

Dr. Ravnskov pointed out a few minor errors:

“On page 121 the book states that ‘unsaturated dietary fats replenish damaged oxidized lipids?and reducing the risk of CVD.’ No dietary trial has been able to prevent CVD mortality by exchanging saturated with unsaturated fat.

“On page 122 the book states that ‘prostaglandins are made from omega-6 type fats (such as olive oil..’ Olive oil contains mainly monounsaturated fatty acids and has very little omega-6.

“On page 138 the book states that the numbers of CVD ‘are still rising.’ This is not true; CVD mortality has indeed gone down in most western countries since the seventies. It has of course been claimed that the reason is cholesterol lowering treatments, but this is pure speculation. More likely causes are the decreasing smoking habits, better treatment of acute CVD and early mobilization [exercise] of the patients. Before 1970 heart patients were put to bed for several weeks.”

Dr. Ravnskov promised to mention “How Statin Drugs Really Lower Cholesterol” in his next newsletter and also to members of THINCS (The International Network of Cholesterol Skeptics).

Evans Consulting Services established SUE! Statins! in 2012 to alert the world to the public health menace of Statin Drugs: “Medicine must be taken away from people who are motivated by greed and returned to people who are motivated by compassion,” Evans says.







Find More Depression Press Releases

Singapore Medicine – Breakthrough Development of Cell Therapy Treatment for Cancer


Singapore (PRWEB) October 29, 2008

Singapore has embarked on a cell-based clinical trial that may have far-reaching implications for future cancer research and treatments.

The trial, currently ongoing, involves up to 35 patients of advanced nasopharyngeal cancer (NPC) and will likely be completed in late-2009, says Dr Toh Han Chong, Senior Consultant, Department of Medical Oncology at the National Cancer Center (NCC), Singapore.

Explaining the ground-breaking nature of this trial, Dr Toh says, “What we’re doing is to extract T-cells from the patient’s own blood, then ‘educate’ these cells to recognize certain viral proteins. These T-cells will be expanded into large numbers in the lab and returned back to the patients to fight the cancer.”

T-cells belong to a group of white blood cells (WBCs) called lymphocytes. There are a number of different types of T-cells that act in many ways to identify, directly attack and destroy infectious agents and potentially even cancer cells. Along with other WBCs, they play a major role in the immune system, which guards the body against infection.

Likening the entire operation to growing an army, Dr Toh elaborates, “If we see the T-cells as fresh recruits, what we’re trying to do is train them up to recognize a specific enemy. Once this is done, we then build up this fighting force from platoon to battalion to division strength. When they reach the battle field, they would know how to ‘seek and destroy’ the enemy while sparing the innocents in their midst.”

The T-cell therapy process itself is logistically simple for the patient. All that is needed is about 350 ml of blood, about the volume of a coca-cola can. The culturing of T-cells will take a few months and the programmed new cells will be returned over a series of intravenous infusions. It is hoped that this process, coupled with a course of chemotherapy, will significantly extend survival rates.

According to Dr Toh, nasopharyngeal cancer was selected for two reasons: It is the sixth commonest cancer in Singapore, and is endemic in southern China and South East Asia. It also has a detectable weakness – Epstein-Barr related viral proteins are expressed on the surface of NPC cancer cells, which are useful as therapeutic targets.

Epstein-Barr virus or EBV is a member of the herpes virus family. Most people become infected with it at some point in their lives. Of those affected, the majority suffer nothing more than mild afflictions, such as fever, sore throat or swollen lymph glands. However, some carriers of the virus eventually develop nasopharyngeal carcinoma, or cancer.

To date, only two studies have been done on using T-cells to fight NPC. The first was done by the Center for Cell and Gene Therapy at Baylor College of Medicine in Houston, Texas, while the second was done in Pavia, Italy.

“Singapore is extremely well-placed to perform this trial because NPC is so common in Asia. We can truly become a hub of excellence in this area,” says Dr Toh, whose clinical and research team is in frequent contact with the Centre for Cell and Gene Therapy in Houston.

“We are very grateful to be partnering the Centre for Cell and Gene Therapy. They are actively involved with us in ramping up capabilities, technologies, clinical trials development using adoptive T-cells to fight NPC. Conventional chemotherapy alone for patients with advanced NPC does not provide a cure. This is an alternative new treatment strategy,” said Dr Toh.

Dr Toh’s team, comprising scientists, clinicians, clinician-scientists, researchers and trained nurses, will build up a bench-to-bedside T-cell therapy facility, which is arguably the only one of its kind in Asia.

“T-cell therapy will provide Singapore with a unique opportunity to distinguish ourselves in the region, if not the world. We have the manpower, regulatory framework, infrastructure, the training and the resources, and we are ready to proceed,” says Dr Toh.

About National Cancer Centre

National Cancer Centre (NCC) offers comprehensive cancer treatment with a highly skilled, multi-disciplinary team comprising medical specialists, nurses, counselors and other paramedical professionals to meet the special needs of cancer patients. The Centre uses the latest technologies in cancer treatment to help patients access proven innovative therapies for the best clinical outcomes. PCC’s commitment is to provide a comprehensive holistic treatment of cancers in a safe and comfortable environment, where patients are attended to by caring and experienced staff. (http://www.parkwaycancercentre.com)

About the SingaporeMedicine Initiative

Launched in 2003, SingaporeMedicine is a multi-agency government-industry partnership committed to strengthening Singapore’s position as Asia’s leading medical hub and international health care destination.

Led by the Ministry of Health of Singapore, SingaporeMedicine is supported by three government agencies: the Economic Development Board, which develops industry capabilities, the International Enterprise Singapore, which fosters regionalism by Singapore-based health care players, and the Singapore Tourism Board, which markets Singapore as a healthcare destination to inbound international patients and develops associated people-oriented services. (http://www.singaporemedicine.com)

###







Related Carcinoma Press Releases

New Type of Stem Cell Preparation Could Bring Pain Relief to Diabetics


Durham, NC (PRWEB) July 09, 2012

A new study released today in STEM CELLS Translational Medicine shows the potential of a new approach in preparing stem cells that provide relief to people suffering from a common, yet painful diabetes complication.

About 70 percent of diabetics have neuropathy, or nerve damage, resulting from the disease, according to the National Institutes of Health. The most common type is peripheral neuropathy (DPN), which causes pain or loss of feeling in the toes, feet, legs, hands and arms. Up to a quarter of DPN sufferers endure an extremely painful version (pDPN) in which even a tiny amount of external pressure can be excruciating.

While there are many contributors to DPN, inflammation is considered a major culprit. Treatments are generally restricted to controlling the diabetes itself and to alleviating pain with topical ointments such as capsaicin cream or with oral medications including antidepressants and anticonvulsants.

?However, none of these therapies directly targets the inflammation, most have negative side effects and less than 30 percent of patients experience adequate pain relief. Clearly, new therapies are needed,? said Dr. Ruth Waterman of the Ochsner Clinic Foundation in New Orleans.

Dr. Waterman collaborated with Dr. Aline Betancourt from Tulane University?s Center for Stem Cell Research and Regenerative Medicine to develop a new treatment for pDPN using modified stem cells to control inflammation. Numerous studies have already proven mesenchymal stem cells (MSCs) are safe and effective in treating inflammatory diseases. MSCs, which are taken from adults, can give rise to a large number of tissue types such as bone, fat and cartilage.

?The problem,? Dr. Betancourt explained, ?is that the current methods for preparing these cells yield a mixed pool of undefined cells that aren?t consistently effective in the clinic. Our laboratory developed a new method that results in a consistent, uniform MSC population and optimizes their anti-inflammatory effects. We call these cells MSC2s.?

When the team tested its MSC2 cells on mice with pDNP, they saw a significant improvement in inflammation and other symptoms ? as much as 40 percent for the MSC2 group over the mice that received no treatment, vs. a 14 percent improvement at best in those administered conventional MSCs.

?Moreover the responses did not differ from what we saw in the healthy control group of mice,? Dr. Waterman said. ?These findings suggest that the use of anti-inflammatory MSC2 is a promising new therapeutic strategy for diabetic peripheral neuropathy that should be further investigated.?

-##-

The full article, ?Anti-Inflammatory Mesenchymal Stem Cells (MSC2) Attenuate Symptoms of Painful Diabetic Peripheral Neuropathy,? can be accessed at http://www.StemCellsTM.com.







Related Diabetes Press Releases

Discovery of Stem Cell Illuminates Human Brain Evolution, Points To Therapies


San Francisco, CA (Vocus) May 26, 2010

UCSF scientists have discovered a new stem cell in the developing human brain. The cell produces nerve cells that help form the neocortex ? the site of higher cognitive function — and likely accounts for the dramatic expansion of the region in the lineages that lead to man, the researchers say.

Future studies of these cells are expected to shed light on developmental diseases such as autism and schizophrenia and malformations of brain development, including microcephaly, lissencephaly and neuronal migration disorders, they say, as well as age-related illnesses, such as Alzheimer?s disease.

Studies also will allow scientists to track the molecular steps that the cell goes through as it evolves into the nerve cell, or neuron, it produces. This information could then be used to prompt embryonic stem cells to differentiate in the culture dish into neurons for potential use in cell-replacement therapy.

The study is reported in a recent issue of the journal Nature, (vol. no. 464, 554-561; issue 7288).

?This discovery has the potential to transform our understanding of the development and evolution of the human neocortex, the most uniquely human part of the central nervous system,? says the senior author of the study, neurologist Arnold Kriegstein, MD, PhD, director of the Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF.

?It also should inform our understanding of developmental diseases and advance the creation of cell-based therapies. Many neurological diseases develop in neurons or the neural circuits between them. If we?re going to understand how these disorders develop, we have to better understand how the human and primate cerebral cortex develops.?

In rodents and humans, the developing cortex contains a layer of neural stem cells called radial glial cells that resides near the fluid-filled ventricles and produces cells that are precursors to neurons. These precursor neurons further proliferate in a region known as the subventricular zone (SVZ), to increase their numbers, and then differentiate into newborn neurons. The neurons then migrate along radial glial fibers up to the neocortex, where they help form the tissue that is the site of sensory perception, motor commands, spatial reasoning, conscious thought and language.

In human and nonhuman primates, however, the SVZ has a massively expanded outer region, known as the outer subventricular zone (OSVZ). About 20 years ago, scientists presumed that the OSVZ also contained stem cells, but until now they have lacked evidence.

In the current study, lead authors David V. Hansen, PhD, a postdoctoral fellow, and Jan H. Lui, a graduate student in the Kriegstein lab, examined the OSVZ, using new labeling and tracking techniques to follow individual cells and their progeny over time in cultured tissue slices from fetal cortex tissue that had been donated for research.

They characterized two kinds of cells within the region — both the novel neural stem cell and its daughter cell, known as the transit amplifying cell. The stem cell closely resembles the radial glial cell in structure and behavior and, like the radial glia, has radial fibers which newborn neurons migrate along up to the neocortex.

The region is a busy hub of cell proliferation. The stem cell undergoes asymmetrical cell division, giving rise to two distinct daughter cells — one a copy of the original stem cell, the other a transit amplifying cell. The transit amplifying cell undergoes multiple rounds of symmetrical divisions before all of its daughter cells begin the process of differentiating into neurons.

?We are very interested in understanding how these modes of division are regulated,? says Kriegstein. ?We suspect that faults in cell-cycle regulation account for a variety of developmental brain diseases.?

More broadly, he says the team wants to understand how the new stem cells compare to radial glial cells and how the two sets of neurons they produce integrate in the neocortex. ?Neurons are probably being generated in both the SVZ and OSVZ at once,? he says. ?They likely end up in the same layer of the neocortex as they migrate into position and start forming circuits.

?This suggests to us that there may be a mosaic of cell types in the human neocortex, in which there are cells that originate in the traditional zone and cells produced in the newer zone that intermix in the cortex. The complexity of primate neocortex may be significantly increased by the interaction of the evolutionarily-speaking ?younger? neurons with those originating in the more primitive zone.?

The massive number of cells within the OSVZ of humans ?tells us we have to be careful when modeling human brain diseases in mice,? says Kriegstein. ?Especially in the neocortex — the most highly developed part of the brain in primates and humans ? there are going to be important differences between rodents and humans.?

The other co-author of the study was Philip R. L. Parker, a graduate student in the Kriegstein lab.

The study was funded by grants from the California Institute for Regenerative Medicine and the Bernard Osher Foundation.

UCSF is a leading university dedicated to promoting health worldwide through advanced biomedical research, graduate-level education in the life sciences and health professions, and excellence in patient care.

Related links:

Nature paper:

http://www.nature.com/nature/journal/v464/n7288/full/nature08845.html

Eli and Edythe Broad Center of Regeneration Medicine and Stem Cell Research at UCSF

http://stemcell.ucsf.edu/

###







Stemedica International And Academic Partner Awarded Swiss Alzheimer?s And Stem Cell Research Grant


Epalinges, Switzerland (PRWEB) May 24, 2012

Stemedica International, Epalinges, Switzerland, a wholly owned subsidiary of Stemedica Cell Technologies, Inc. (San Diego, CA) announced today that it was awarded a grant by the Swiss Commission for Technology and Innovation along with its academic partner, The ?cole Polytechnique F?d?rale de Lausanne (EPFL). The 584,522 CHF (approx. 620,000 USD) grant is focused on the use of EPFL?s advanced imaging capabilities along with Stemedica?s ischemic tolerant stem cells and stem cell factors in transgenic mouse models of Alzheimer?s disease. The basic research supports Stemedica?s clinical trial advancement for Alzheimer?s disease for both Switzerland and the United States.

?We are pleased that we will be collaborating with one of the world?s leading technical academic institutions,? said Nikolai Tankovich, MD, PhD, Executive Chairman of Stemedica International. ?We will be able to see the therapeutic potential of our ischemia tolerant neural and mesenchymal cells, as well as the impact of our stem cell factors on the amyloid plaque pathology and brain vascularization associated with Alzheimer?s disease. ?

EPFL has developed sophisticated imaging methods that allow for the visualization of amyloid plaques without the need of injecting amyloid-binding dyes / contrast agents. In addition to visualizing amyloid plaques, the precise, femtosecond laser system allows imaging of quantitative blood flow and other critical functional parameters.

Professor Theo Lasser, Head of Laboratoire d?Optique Biomedicale (LOB), EPFL, commented, ?We are excited to collaborate with the world?s leading manufacturer of allogeneic stem cells and apply our methods of Optical Coherent Microscopy developed at LOB, EPFL to potentially find a cure for Alzheimer?s disease. ?

Tristan Bolmont, PhD, of EPFL will lead the research project, along with Alexei Lukashev, PhD., Director of the Laser Stem Cell Division, Stemedica. Dr. Bolmont commented on the scope of the project, ?The scale of this project, treating and imaging more than 140 subjects, will allow us to make the correlations that are critical to understanding the pathophysiology of this disease. Furthermore, we will better understand the biodistribution and the mechanism of action of Stemedica?s ischemia tolerant neural and mesenchymal stem cells and how they affect the Alzheimer?s altered brain.?

According to Roger Howe, PhD, President of Stemedica International, ?The Swiss government is being remarkably progressive in bridging the gap between bench top research and translational medicine. We greatly appreciate their support in documenting stem cell effectiveness in neurological diseases.?

For more information please contact Dave McGuigan at dmcguigan (at) stemedica.com

About Stemedica Cell Technologies, Inc.

Stemedica Cell Technologies, Inc. is a specialty bio-pharmaceutical company committed to the manufacturing and development of best-in-class allogeneic adult stem cells and stem cell factors for use by approved research institutions and hospitals for pre-clinical and clinical (human) trials. The company is a government licensed manufacturer of clinical grade stem cells and is approved by the FDA for its clinical trials for ischemic stroke. Stemedica is currently developing regulatory pathways for a number of medical indications using adult allogeneic stem cells. The Company is headquartered in San Diego, California.

About The ?cole Polytechnique F?d?rale de Lausanne (EPFL)

The EPFL is one of the two Swiss Federal Institutes of Technology is located in Lausanne, Switzerland. The school was founded by the Swiss Federal Government with the stated mission to (a) educate engineers and scientists, (b) be a national center of excellence in science and technology, (c) provide a hub for interaction between the scientific community and industry. The sister institution in the German-speaking part of Switzerland is the Eidgen?ssische Technische Hochschule Z?rich (ETH Z?rich or ETHZ). Associated with several specialized research institutes, the two sister institutes form the ETH Domain. EPFL is ranked among the top academic institutions in the world.







Find More Alzheimers Press Releases

Eye Patients get New Stem Cell Treatment by American Retinal Surgeon

Margate, FL (PRWEB) June 05, 2012

An American Retinal Surgeon from Florida has just finished treating 7 patients with a new technique he developed for administrating adult stem cells for eye disease. MD Stem Cells, a consultancy helping patients access leading stem cell providers in both the US and Europe – http://www.mdstemcells.com – made the announcement. “Our affiliate retinal surgeon traveled to Vienna, Austria to provide the new treatment to an international group of patients”, explained Dr Levy, Senior Consultant at MD Stem Cells. ” We are extremely pleased that this new procedure is now available and being provided on a routine basis”. Patients came from the United States, Austria and Romania to obtain the adult stem cell treatment. They ranged in age from 2 years to 87 years old and suffered from a variety of eye diseases including AMD or Age Related Macular Degeneration, Myopic Macular Degeneration, Bulls Eye Retinopathy- a type of hereditary retinal disease , Retinitis Pigmentosa, and Optic Nerve Disease. All the patients did well and were very pleased with the treatment.

Adult Stem Cells are stem cells taken directly from the patients own body avoiding the problems associated with embryonic or fetal stem cells. They are typically obtained from the bone marrow where there is a high concentration of specific types of stem cells found to be useful for many diseases. At times they are obtained from the blood directly. Adult Stem Cells are now used to treat a number of different medical conditions including diabetes, renal failure, strokes, cerebral palsy, autism, Parkinson’s, multiple sclerosis, COPD, heart disease and liver disease- in addition to ophthalmology problems.

Previously the stem cells were injected behind the eye to treat ophthalmic problems but the exact location and how far they might be from the targeted retinal or optic nerve tissue was not always known. In part, the variability in visual response to stem cell treatments has been thought to be from the difference in positioning of the stem cells and how far they were from the diseased area of the eye itself.

“Now with the new technique the stem cells can be placed precisely adjacent to the eye in a very safe manner,” relayed Dr Levy. As an analogy, if your hand was the eye and a glove the surrounding tissue, the new technique allows the stem cells to be injected at the top of the glove and directed down to the exact fingertips the surgeon chooses. The doctor has performed retinal surgery previously to inject stem cells, but believes the risk-benefit for many patients now favors his new non-surgical technique. ” Our surgeon notes that his approach avoids the risks of surgery yet allows him to precisely place the stem cells adjacent to the diseased part of the eye or the optic nerve for best effect”, relayed Dr Levy.

The operating room at the Vienna International Medical Clinic Hospital was crowded with other physicians and health professionals from Vienna, Austria observing and recording the procedures. All the patients did well and were very pleased with the treatment.

“We’re fortunate to be working with such an experienced retinal ophthalmologist,” remarked Dr Levy. “He completed two retinal fellowships at Harvard, MIT and New England Deaconess Hospitals. His strong training and prior experience with stem cell treatments inspires confidence in patients and reassures physicians who may be referring or supporting their patients.”

MD Stem Cells is a stem cell consultancy working directly with leading physicians and surgeons as providing stem cell treatments both in the United States and Europe. Many conditions can be treated and MD Stem Cells is available to discuss options with patients and interested or referring physicians. Their website is http://www.mdstemcells.com and they may be reached at 203-423-9494.







Cell Therapy now being used for carpal tunnel syndrome at the Center for Regenerative Medicine


(PRWEB) May 20, 2012

Cell Therapy now being used for carpal tunnel syndrome at the Center for Regenerative Medicine. “Current studies seem to be very impressive with use of regenerative medicine in orhopedic problems”. A.J. Farshchian MD From the center for regenerative medicine said earlier in a discussion on arthritis and sports injuries.

“Current studies seem to be very impressive with use of regenerative medicine in orhopedic problems”. A.J. Farshchian MD From the center for regenerative medicine said earlier in a discussion on arthritis and sports injuries.

Carpal tunnel syndrome occurs when the median nerve, which runs from the forearm into the hand, becomes pressed or squeezed at the wrist. The median nerve controls sensations to the palm side of the thumb and fingers except for the fifth digit or also known as little finger, Median nerve also carries impulses to some small muscles in the hand that allow the fingers to move. The carpal tunnel is a narrow, rigid passageway of ligament and bones at the base of the hand which contains the median nerve.

Sometimes, thickening from irritated tendons or other swelling narrows the tunnel and causes the median nerve to be compressed. The result may be pain, weakness, or numbness in the hand and wrist, radiating up the arm. Although painful sensations may indicate other conditions, carpal tunnel syndrome is the most common and widely known of the entrapment neuropathies in which the body’s peripheral nerves are compressed or traumatized Symptoms of Carpal tunnel syndrome starts gradually, with frequent burning, tingling, or itching numbness in the palm of the hand and the fingers, especially the thumb and the index and middle fingers. Some carpal tunnel sufferers say their fingers feel useless and swollen, even though little or no swelling is apparent.

The symptoms often first appear in one or both hands during the night, since many people sleep with flexed wrists. A very common symptom is the patient may wake up from sleep, feeling the need to “shake out” the hand or wrist. As symptoms worsen, people might feel tingling during the day. Decreased grip strength may make it difficult to form a fist, grasp small objects, or perform other manual tasks. In chronic and/or untreated cases, the muscles at the base of the thumb may waste away. Some people are unable to tell between hot and cold by touch.

Carpal tunnel syndrome is often the result of a combination of factors that increase pressure on the median nerve and tendons in the carpal tunnel, rather than a problem with the nerve itself. There may be a genetic factor since the carpal tunnel is simply smaller in some people than in others. Other contributing factors include trauma or injury to the wrist that cause swelling, such as sprain or fracture, mechanical problems in the wrist joint, fluid retention during pregnancy or menopause, work stress, repeated use of vibrating hand tools rare causes such as over activity of the pituitary gland; hypothyroidism; rheumatoid arthritis; or the development of a cyst or tumor in the canal are possible as well. There is little clinical data to prove whether repetitive and forceful movements of the hand and wrist during work or leisure activities can cause carpal tunnel syndrome.

Repeated motions performed in the course of normal work or other daily activities can result in repetitive motion disorders such as bursitis and tendonitis. Women are three times more likely than men to develop carpal tunnel syndrome, perhaps because the carpal tunnel itself may be smaller in women than in men. The dominant hand is usually affected first and produces the most severe pain. Persons with diabetes or other metabolic disorders that directly affect the body’s nerves and make them more susceptible to compression are also at high risk. Carpal tunnel syndrome usually occurs only in adults.

The risk of developing carpal tunnel syndrome is not confined to people in a single industry or job, but is especially common in those performing assembly line work – manufacturing, sewing, finishing, cleaning, and meat, poultry, or fish packing. In fact, carpal tunnel syndrome is three times more common among assemblers than among data-entry personnel. A 2001 study by the Mayo Clinic found heavy computer use (up to 7 hours a day) did not increase a person’s risk of developing carpal tunnel syndrome.

According recent data an estimated 3/ 10,000 workers lost time from work because of carpal tunnel syndrome. Half of these workers missed more than 10 days of work. The average lifetime cost of carpal tunnel syndrome, including medical bills and lost time from work, is estimated to be about $ 30,000 for each injured worker. Early diagnosis and treatment are important to avoid permanent damage to the median nerve. A physical examination of the hands including Tapping over the carpal tunnel may result in tingling sensation in the distribution of the median nerve in carpal tunnel syndrome. This is known as Tinel?s sign. Another exam is Phalen?s test which while the wrists are held in flexion for 60 seconds or less and patient begins to experience symptoms. (see picture). The wrist is also examined for tenderness, swelling, warmth, and discoloration. Ultrasound of the median nerve is also usually useful.

The Center for Regenerative Medicine in Miami, Florida concentrates on helping arthritic and injured people to get back to a functional level of life and their activities using non-surgical techniques and Orthopedic medicine. The center’s expertise is in treatment of conditions of spine, knees , shoulders , and other cartilage damages. We have developed non-surgical and rehabilitation techniques focused on treatment and management of joint pain. Our team includes health professionals organized around a central theme.







Powered by WordPress | Designed by: best suv | Thanks to toyota suv, infiniti suv and lexus suv